Personalized Medicine in Cardiovascular and Metabolic Diseases

A special issue of Journal of Personalized Medicine (ISSN 2075-4426). This special issue belongs to the section "Mechanisms of Diseases".

Deadline for manuscript submissions: 31 December 2026 | Viewed by 1049

Special Issue Editor


E-Mail Website
Guest Editor
1. Departments of Medicine and Molecular Pharmacology, Wilf Family Cardiovascular Research Institute, Fleischer Institute for Diabetes and Metabolism (FIDAM), Einstein Institute for Aging Research, Einstein-Mount Sinai Diabetes Research Center (ES-DRC), Institute for Neuroimmunology and Inflammation (INI), Albert Einstein College of Medicine and Montefiore Hospital, New York, NY, USA
2. International Translational Research and Medical Education (ITME) Consortium, Academic Research Unit, Department of Advanced Biomedical Sciences, Federico II University, Naples, Italy
Interests: cardiology; hypertension; restenosis; heart failure; myocardial infarction; endothelial dysfunction; mitochondria; diabetes; microRNAs; insulin resistance; atherosclerosis; thrombosis; cardiac hypertrophy; pancreatic beta cell function; insulin release
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

As the global burden of cardiovascular and metabolic disorders continues to rise, the need for individualized approaches to prevention, diagnosis, and treatment has never been greater. Advances in genomics, multi-omics, imaging, digital health, and biomarker discovery are transforming our understanding of disease mechanisms and enabling tailored interventions that improve outcomes and minimize adverse effects. The Special Issue “Personalized Medicine in Cardiovascular and Metabolic Diseases” aims to highlight cutting-edge research, clinical studies, and technological innovations that drive the development and implementation of personalized medicine in cardiovascular and metabolic care. We welcome original research articles and reviews that explore a wide range of topics, including but not limited to:

  • Genomic and epigenomic predictors of cardiovascular and metabolic risk;
  • Multi-omics integration for disease stratification and therapeutic targeting;
  • AI and machine learning tools in personalized risk assessment and decision-making;
  • Novel biomarkers for individualized therapy monitoring;
  • Pharmacogenomics and tailored pharmacologic interventions;
  • Precision approaches to diabetes, obesity, dyslipidemia, and hypertension;
  • Sex-specific and ancestry-informed strategies in cardiometabolic health;
  • Personalized prevention and digital therapeutics in population health.

Contributions from interdisciplinary teams that bridge basic science, clinical research, and health informatics are especially encouraged. Submissions should emphasize translational potential, clinical applicability, and future directions in the field. All manuscripts will undergo rigorous peer review and be published open access, ensuring broad visibility and impact. Join us in shaping the future of precision medicine in cardiovascular and metabolic disease care.

Dr. Gaetano Santulli
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Personalized Medicine is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • cardiovascular disease
  • metabolic syndrome
  • precision health
  • telemedicine
  • biomarkers
  • pharmacogenomics
  • artificial intelligence
  • machine learning
  • epigenetics
  • diabetes

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Other

17 pages, 1981 KB  
Systematic Review
Cardiovascular and Thromboembolic Risk of Janus Kinase Inhibitors Compared to Other Disease-Modifying Drugs in Patients with Rheumatoid Arthritis: A Systematic Review and Meta-Analysis
by Diomidis C. Ioannidis, Efthymia Maria Kapasouri, Vassilios S. Vassiliou and Eleana Ntatsaki
J. Pers. Med. 2026, 16(2), 113; https://doi.org/10.3390/jpm16020113 - 13 Feb 2026
Viewed by 605
Abstract
Background/Objectives: Janus Kinase inhibitors (JAKi) are an effective treatment option for rheumatoid arthritis (RA); however, emerging concerns regarding cardiovascular and thromboembolic risk have prompted further investigation. We conducted a systematic review and meta-analysis to compare the risk of major adverse cardiovascular events [...] Read more.
Background/Objectives: Janus Kinase inhibitors (JAKi) are an effective treatment option for rheumatoid arthritis (RA); however, emerging concerns regarding cardiovascular and thromboembolic risk have prompted further investigation. We conducted a systematic review and meta-analysis to compare the risk of major adverse cardiovascular events (MACE) and venous thromboembolism (VTE) in patients receiving JAKi versus other disease-modifying anti-rheumatic drugs (DMARDs). Methods: Following PRISMA 2020 guidelines and a preregistered protocol, we systematically searched PubMed, Embase, and the Cochrane Library. Observational studies and randomized controlled trials (RCTs) reporting MACE or VTE among adults with RA treated with JAKi or comparator DMARDs were included. Hazard ratios (HRs) from observational studies and odds ratios (ORs) from RCTs were pooled using fixed- or random-effects models depending on heterogeneity. A sensitivity analysis was conducted for participants aged ≥ 65 years. Results: Twenty-five observational studies and eight RCTs were included. Across observational studies, the pooled HRs for MACE showed no significant difference between JAKi and other DMARDs, HR = 0.98, 95% CI = 0.85–1.13. This finding remained consistent in individuals aged ≥ 65 years. No increase in MACE risk was observed across RCTs, OR = 1.27, 95% CI = 0.89–1.81. In contrast, JAKi use was associated with a significantly higher risk of VTE in the observational studies (HR = 1.32, 95% CI = 1.08–1.61) but not in the RCTs (OR = 1.69, 95% CI = 0.94–3.02). Conclusions: JAKi use does not appear to increase the risk of MACE compared to DMARDs, including in older adults, but may be associated with a higher risk of VTE. These findings highlight the importance of a personalized approach when considering JAKi therapy, incorporating structured cardiovascular and thrombotic risk assessment, patient preferences, and mitigation of modifiable risk factors. Full article
(This article belongs to the Special Issue Personalized Medicine in Cardiovascular and Metabolic Diseases)
Show Figures

Figure 1

Back to TopTop